CHECKPOINT THERAPEUTICS INC (CKPT)

US1628282063 - Common Stock

2.0708  +0.03 (+1.51%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CKPT. CKPT was compared to 592 industry peers in the Biotechnology industry. Both the profitability and financial health of CKPT have multiple concerns. CKPT is quite expensive at the moment. It does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

CKPT had negative earnings in the past year.
CKPT had a negative operating cash flow in the past year.
In the past 5 years CKPT always reported negative net income.
In the past 5 years CKPT always reported negative operating cash flow.

1.2 Ratios

CKPT has a Return On Assets of -2420.27%. This is amonst the worse of the industry: CKPT underperforms 99.49% of its industry peers.
Industry RankSector Rank
ROA -2420.27%
ROE N/A
ROIC N/A
ROA(3y)-209.01%
ROA(5y)-172.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CKPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

The number of shares outstanding for CKPT has been reduced compared to 1 year ago.
CKPT has more shares outstanding than it did 5 years ago.
CKPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -282.12, we must say that CKPT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -282.12, CKPT is doing worse than 98.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -282.12
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CKPT has a Current Ratio of 0.10. This is a bad value and indicates that CKPT is not financially healthy enough and could expect problems in meeting its short term obligations.
CKPT has a Current ratio of 0.10. This is amonst the worse of the industry: CKPT underperforms 98.98% of its industry peers.
CKPT has a Quick Ratio of 0.10. This is a bad value and indicates that CKPT is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CKPT (0.10) is worse than 98.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.05% over the past year.
Looking at the last year, CKPT shows a very strong growth in Revenue. The Revenue has grown by 21.43%.
CKPT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.71% yearly.
EPS 1Y (TTM)48.05%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q75.83%
Revenue 1Y (TTM)21.43%
Revenue growth 3Y-51.92%
Revenue growth 5Y-35.71%
Revenue growth Q2Q-40%

3.2 Future

Based on estimates for the next years, CKPT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.04% on average per year.
The Revenue is expected to grow by 851.23% on average over the next years. This is a very strong growth
EPS Next Y61.68%
EPS Next 2Y34.59%
EPS Next 3Y28.04%
EPS Next 5YN/A
Revenue Next Year10.27%
Revenue Next 2Y860.49%
Revenue Next 3Y851.23%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

CKPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CKPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CKPT's earnings are expected to grow with 28.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.59%
EPS Next 3Y28.04%

0

5. Dividend

5.1 Amount

No dividends for CKPT!.
Industry RankSector Rank
Dividend Yield N/A

CHECKPOINT THERAPEUTICS INC

NASDAQ:CKPT (3/28/2024, 2:36:29 PM)

2.0708

+0.03 (+1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap50.49M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2420.27%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)48.05%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y61.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.43%
Revenue growth 3Y-51.92%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y